Articles - 2exm mentioned but not cited (2)
- A multiplex human syndrome implicates a key role for intestinal cell kinase in development of central nervous, skeletal, and endocrine systems. Lahiry P, Wang J, Robinson JF, Turowec JP, Litchfield DW, Lanktree MB, Gloor GB, Puffenberger EG, Strauss KA, Martens MB, Ramsay DA, Rupar CA, Siu V, Hegele RA. Am J Hum Genet 84 134-147 (2009)
- Molecular Dynamics Simulations and Classical Multidimensional Scaling Unveil New Metastable States in the Conformational Landscape of CDK2. Pisani P, Caporuscio F, Carlino L, Rastelli G. PLoS One 11 e0154066 (2016)
Reviews citing this publication (21)
- The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Vermeulen K, Van Bockstaele DR, Berneman ZN. Cell Prolif 36 131-149 (2003)
- Pharmacological inhibitors of cyclin-dependent kinases. Knockaert M, Greengard P, Meijer L. Trends Pharmacol Sci 23 417-425 (2002)
- Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Mazanetz MP, Fischer PM. Nat Rev Drug Discov 6 464-479 (2007)
- Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Traxler P, Furet P. Pharmacol Ther 82 195-206 (1999)
- Magic bullets for protein kinases. Bishop AC, Buzko O, Shokat KM. Trends Cell Biol 11 167-172 (2001)
- Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Fabbro D, Ruetz S, Buchdunger E, Cowan-Jacob SW, Fendrich G, Liebetanz J, Mestan J, O'Reilly T, Traxler P, Chaudhuri B, Fretz H, Zimmermann J, Meyer T, Caravatti G, Furet P, Manley PW. Pharmacol Ther 93 79-98 (2002)
- Structural modes of stabilization of permissive phosphorylation sites in protein kinases: distinct strategies in Ser/Thr and Tyr kinases. Krupa A, Preethi G, Srinivasan N. J Mol Biol 339 1025-1039 (2004)
- CDK inhibition and cancer therapy. Garrett MD, Fattaey A. Curr Opin Genet Dev 9 104-111 (1999)
- Structure-based design of cyclin-dependent kinase inhibitors. Davies TG, Pratt DJ, Endicott JA, Johnson LN, Noble ME. Pharmacol Ther 93 125-133 (2002)
- Cyclin-dependent kinase inhibitors: novel anticancer agents. Mani S, Wang C, Wu K, Francis R, Pestell R. Expert Opin Investig Drugs 9 1849-1870 (2000)
- Selectivity and potency of cyclin-dependent kinase inhibitors. Sridhar J, Akula N, Pattabiraman N. AAPS J 8 E204-21 (2006)
- Structures of staurosporine bound to CDK2 and cAPK--new tools for structure-based design of protein kinase inhibitors. Toledo LM, Lydon NB. Structure 5 1551-1556 (1997)
- Catalytic subunit of cyclic AMP-dependent protein kinase: structure and dynamics of the active site cleft. Taylor SS, Radzio-Andzelm E, Madhusudan, Cheng X, Ten Eyck L, Narayana N. Pharmacol Ther 82 133-141 (1999)
- Pharmacological targeting of CDK9 in cardiac hypertrophy. Krystof V, Chamrád I, Jorda R, Kohoutek J. Med Res Rev 30 646-666 (2010)
- Natural products as kinase inhibitors. Liu J, Hu Y, Waller DL, Wang J, Liu Q. Nat Prod Rep 29 392-403 (2012)
- Chemical inhibitors of cyclin-dependent kinases: insights into design from X-ray crystallographic studies. Noble ME, Endicott JA. Pharmacol Ther 82 269-278 (1999)
- Protein kinase inhibition: natural and synthetic variations on a theme. Taylor SS, Radzio-Andzelm E. Curr Opin Chem Biol 1 219-226 (1997)
- The role of cyclin-dependent kinase 5 in neuropathic pain. Gomez K, Vallecillo TGM, Moutal A, Perez-Miller S, Delgado-Lezama R, Felix R, Khanna R. Pain 161 2674-2689 (2020)
- Differentiation of human myeloid leukemia cells by plant redifferentiation-inducing hormones. Honma Y, Ishii Y. Leuk Lymphoma 43 1729-1735 (2002)
- Conformational diversity of catalytic cores of protein kinases. Sowadski JM, Epstein LF, Lankiewicz L, Karlsson R. Pharmacol Ther 82 157-164 (1999)
- Cyclin-dependent kinases as new targets for the prevention and treatment of cancer. Senderowicz AM. Hematol Oncol Clin North Am 16 1229-1253 (2002)
Articles citing this publication (84)
- Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N, Inagaki M, Delcros JG, Moulinoux JP. Eur J Biochem 243 527-536 (1997)
- Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Mohammadi M, McMahon G, Sun L, Tang C, Hirth P, Yeh BK, Hubbard SR, Schlessinger J. Science 276 955-960 (1997)
- Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Kornev AP, Haste NM, Taylor SS, Eyck LF. Proc Natl Acad Sci U S A 103 17783-17788 (2006)
- Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Hoessel R, Leclerc S, Endicott JA, Nobel ME, Lawrie A, Tunnah P, Leost M, Damiens E, Marie D, Marko D, Niederberger E, Tang W, Eisenbrand G, Meijer L. Nat Cell Biol 1 60-67 (1999)
- Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. De Azevedo WF, Leclerc S, Meijer L, Havlicek L, Strnad M, Kim SH. Eur J Biochem 243 518-526 (1997)
- Structural changes involved in protein binding correlate with intrinsic motions of proteins in the unbound state. Tobi D, Bahar I. Proc Natl Acad Sci U S A 102 18908-18913 (2005)
- A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Tong L, Pav S, White DM, Rogers S, Crane KM, Cywin CL, Brown ML, Pargellis CA. Nat Struct Biol 4 311-316 (1997)
- Structural basis of inhibitor selectivity in MAP kinases. Wang Z, Canagarajah BJ, Boehm JC, Kassisà S, Cobb MH, Young PR, Abdel-Meguid S, Adams JL, Goldsmith EJ. Structure 6 1117-1128 (1998)
- A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Fedorov O, Marsden B, Pogacic V, Rellos P, Müller S, Bullock AN, Schwaller J, Sundström M, Knapp S. Proc Natl Acad Sci U S A 104 20523-20528 (2007)
- Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. De Azevedo WF, Mueller-Dieckmann HJ, Schulze-Gahmen U, Worland PJ, Sausville E, Kim SH. Proc Natl Acad Sci U S A 93 2735-2740 (1996)
- Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent. Meijer L, Thunnissen AM, White AW, Garnier M, Nikolic M, Tsai LH, Walter J, Cleverley KE, Salinas PC, Wu YZ, Biernat J, Mandelkow EM, Kim SH, Pettit GR. Chem Biol 7 51-63 (2000)
- The structure of mitogen-activated protein kinase p38 at 2.1-A resolution. Wang Z, Harkins PC, Ulevitch RJ, Han J, Cobb MH, Goldsmith EJ. Proc Natl Acad Sci U S A 94 2327-2332 (1997)
- Structure of Mycobacterium tuberculosis PknB supports a universal activation mechanism for Ser/Thr protein kinases. Young TA, Delagoutte B, Endrizzi JA, Falick AM, Alber T. Nat Struct Biol 10 168-174 (2003)
- Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors. Knockaert M, Gray N, Damiens E, Chang YT, Grellier P, Grant K, Fergusson D, Mottram J, Soete M, Dubremetz JF, Le Roch K, Doerig C, Schultz P, Meijer L. Chem Biol 7 411-422 (2000)
- Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription. Schang LM, Phillips J, Schaffer PA. J Virol 72 5626-5637 (1998)
- Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. Chang YT, Gray NS, Rosania GR, Sutherlin DP, Kwon S, Norman TC, Sarohia R, Leost M, Meijer L, Schultz PG. Chem Biol 6 361-375 (1999)
- Sequential dephosphorylation of p34(cdc2) on Thr-14 and Tyr-15 at the prophase/metaphase transition. Borgne A, Meijer L. J Biol Chem 271 27847-27854 (1996)
- Inhibiting cell cycle progression reduces reactive astrogliosis initiated by scratch injury in vitro and by cerebral ischemia in vivo. Zhu Z, Zhang Q, Yu Z, Zhang L, Tian D, Zhu S, Bu B, Xie M, Wang W. Glia 55 546-558 (2007)
- Staurosporine-induced conformational changes of cAMP-dependent protein kinase catalytic subunit explain inhibitory potential. Prade L, Engh RA, Girod A, Kinzel V, Huber R, Bossemeyer D. Structure 5 1627-1637 (1997)
- Cyclin C/CDK8 and cyclin H/CDK7/p36 are biochemically distinct CTD kinases. Rickert P, Corden JL, Lees E. Oncogene 18 1093-1102 (1999)
- Inhibitor binding to active and inactive CDK2: the crystal structure of CDK2-cyclin A/indirubin-5-sulphonate. Davies TG, Tunnah P, Meijer L, Marko D, Eisenbrand G, Endicott JA, Noble ME. Structure 9 389-397 (2001)
- Transcription of herpes simplex virus immediate-early and early genes is inhibited by roscovitine, an inhibitor specific for cellular cyclin-dependent kinases. Schang LM, Rosenberg A, Schaffer PA. J Virol 73 2161-2172 (1999)
- Levels of endogenous cytokinins, indole-3-acetic acid and abscisic acid during the cell cycle of synchronized tobacco BY-2 cells. Redig P, Shaul O, Inze D, Van Montagu M, Van Onckelen H. FEBS Lett 391 175-180 (1996)
- Roscovitine, a specific inhibitor of cellular cyclin-dependent kinases, inhibits herpes simplex virus DNA synthesis in the presence of viral early proteins. Schang LM, Rosenberg A, Schaffer PA. J Virol 74 2107-2120 (2000)
- Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol. de Azevedo WF, Canduri F, da Silveira NJ. Biochem Biophys Res Commun 293 566-571 (2002)
- Zeatin is indispensable for the G2-M transition in tobacco BY-2 cells. Laureys F, Dewitte W, Witters E, Van Montagu M, Inzé D, Van Onckelen H. FEBS Lett 426 29-32 (1998)
- Activation and inhibition of cyclin-dependent kinase-2 by phosphorylation; a molecular dynamics study reveals the functional importance of the glycine-rich loop. Bártová I, Otyepka M, Kríz Z, Koca J. Protein Sci 13 1449-1457 (2004)
- The CRK3 protein kinase is essential for cell cycle progression of Leishmania mexicana. Hassan P, Fergusson D, Grant KM, Mottram JC. Mol Biochem Parasitol 113 189-198 (2001)
- Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4. Soni R, O'Reilly T, Furet P, Muller L, Stephan C, Zumstein-Mecker S, Fretz H, Fabbro D, Chaudhuri B. J Natl Cancer Inst 93 436-446 (2001)
- Diversity-Based Organic Synthesis in the Era of Genomics and Proteomics NRC publication no. 43843. David Thomas is a senior colleague and mentor. Arya P, Chou DT, Baek MG. Angew Chem Int Ed Engl 40 339-346 (2001)
- Crystal structure of the protein kinase domain of yeast AMP-activated protein kinase Snf1. Rudolph MJ, Amodeo GA, Bai Y, Tong L. Biochem Biophys Res Commun 337 1224-1228 (2005)
- Alternative binding modes of an inhibitor to two different kinases. De Moliner E, Brown NR, Johnson LN. Eur J Biochem 270 3174-3181 (2003)
- Design and synthesis of Rho kinase inhibitors (I). Takami A, Iwakubo M, Okada Y, Kawata T, Odai H, Takahashi N, Shindo K, Kimura K, Tagami Y, Miyake M, Fukushima K, Inagaki M, Amano M, Kaibuchi K, Iijima H. Bioorg Med Chem 12 2115-2137 (2004)
- Hit-to-lead studies on benzimidazole inhibitors of ITK: discovery of a novel class of kinase inhibitors. Snow RJ, Abeywardane A, Campbell S, Lord J, Kashem MA, Khine HH, King J, Kowalski JA, Pullen SS, Roma T, Roth GP, Sarko CR, Wilson NS, Winters MP, Wolak JP, Cywin CL. Bioorg Med Chem Lett 17 3660-3665 (2007)
- Letter How to choose relevant multiple receptor conformations for virtual screening: a test case of Cdk2 and normal mode analysis. Sperandio O, Mouawad L, Pinto E, Villoutreix BO, Perahia D, Miteva MA. Eur Biophys J 39 1365-1372 (2010)
- Synthesis and biological evaluations of pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 inhibitors. Kim DC, Lee YR, Yang BS, Shin KJ, Kim DJ, Chung BY, Yoo KH. Eur J Med Chem 38 525-532 (2003)
- Hot spot analysis for driving the development of hits into leads in fragment-based drug discovery. Hall DR, Ngan CH, Zerbe BS, Kozakov D, Vajda S. J Chem Inf Model 52 199-209 (2012)
- Classification of proteins based on the properties of the ligand-binding site: the case of adenine-binding proteins. Cappello V, Tramontano A, Koch U. Proteins 47 106-115 (2002)
- Structure-guided discovery of cyclin-dependent kinase inhibitors. Fischmann TO, Hruza A, Duca JS, Ramanathan L, Mayhood T, Windsor WT, Le HV, Guzi TJ, Dwyer MP, Paruch K, Doll RJ, Lees E, Parry D, Seghezzi W, Madison V. Biopolymers 89 372-379 (2008)
- Cytokinin-induced differentiation of human myeloid leukemia HL-60 cells is associated with the formation of nucleotides, but not with incorporation into DNA or RNA. Ishii Y, Sakai S, Honma Y. Biochim Biophys Acta 1643 11-24 (2003)
- Structural basis for selectivity of the isoquinoline sulfonamide family of protein kinase inhibitors. Xu RM, Carmel G, Kuret J, Cheng X. Proc Natl Acad Sci U S A 93 6308-6313 (1996)
- The therapeutic potential of targeting the cell cycle. Webster KR. Expert Opin Investig Drugs 7 865-887 (1998)
- Characterization of novel inhibitors of cyclin-dependent kinases. Kent LL, Hull-Campbell NE, Lau T, Wu JC, Thompson SA, Nori M. Biochem Biophys Res Commun 260 768-774 (1999)
- Molecular models of cyclin-dependent kinase 1 complexed with inhibitors. Canduri F, Uchoa HB, de Azevedo WF. Biochem Biophys Res Commun 324 661-666 (2004)
- Structural aspects of the functional modules in human protein kinase-C alpha deduced from comparative analyses. Srinivasan N, Bax B, Blundell TL, Parker PJ. Proteins 26 217-235 (1996)
- Transferable scoring function based on semiempirical quantum mechanical PM6-DH2 method: CDK2 with 15 structurally diverse inhibitors. Dobeš P, Fanfrlík J, Rezáč J, Otyepka M, Hobza P. J Comput Aided Mol Des 25 223-235 (2011)
- A computational study of the protein-ligand interactions in CDK2 inhibitors: using quantum mechanics/molecular mechanics interaction energy as a predictor of the biological activity. Alzate-Morales JH, Contreras R, Soriano A, Tuñon I, Silla E. Biophys J 92 430-439 (2007)
- Bisubstrate analog probes for the insulin receptor protein tyrosine kinase: molecular yardsticks for analyzing catalytic mechanism and inhibitor design. Hines AC, Parang K, Kohanski RA, Hubbard SR, Cole PA. Bioorg Chem 33 285-297 (2005)
- Identification of High-Affinity Inhibitors of Cyclin-Dependent Kinase 2 Towards Anticancer Therapy. Mohammad T, Batra S, Dahiya R, Baig MH, Rather IA, Dong JJ, Hassan I. Molecules 24 E4589 (2019)
- Survival-promoting activity of inhibitors of cyclin-dependent kinases on primary neurons correlates with inhibition of c-Jun kinase-1. Markus MA, Kahle PJ, Winkler A, Horstmann S, Anneser JM, Borasio GD. Neurobiol Dis 4 122-133 (1997)
- Structural basis for the GSK-3beta binding affinity and selectivity against CDK-2 of 1-(4-aminofurazan-3yl)-5-dialkylaminomethyl-1H-[1,2,3] triazole-4-carboxylic acid derivatives. Pande V, Ramos MJ. Bioorg Med Chem Lett 15 5129-5135 (2005)
- Classical anticytokinins do not interact with cytokinin receptors but inhibit cyclin-dependent kinases. Spíchal L, Krystof V, Paprskárová M, Lenobel R, Styskala J, Binarová P, Cenklová V, De Veylder L, Inzé D, Kontopidis G, Fischer PM, Schmülling T, Strnad M. J Biol Chem 282 14356-14363 (2007)
- Dynamics and binding modes of free cdk2 and its two complexes with inhibitors studied by computer simulations. Otyepka M, Kríz Z, Koca J. J Biomol Struct Dyn 20 141-154 (2002)
- The CRK1 receptor-like kinase gene of tobacco is negatively regulated by cytokinin. Schäfer S, Schmülling T. Plant Mol Biol 50 155-166 (2002)
- The effect of a tightly bound water molecule on scaffold diversity in the computer-aided de novo ligand design of CDK2 inhibitors. García-Sosa AT, Mancera RL. J Mol Model 12 422-431 (2006)
- Expansion of cyclin D and CDK1 paralogs in Oikopleura dioica, a chordate employing diverse cell cycle variants. Campsteijn C, Ovrebø JI, Karlsen BO, Thompson EM. Mol Biol Evol 29 487-502 (2012)
- Pyrazolo[3,4-b]quinoxalines. A new class of cyclin-dependent kinases inhibitors. Ortega MA, Montoya ME, Zarranz B, Jaso A, Aldana I, Leclerc S, Meijer L, Monge A. Bioorg Med Chem 10 2177-2184 (2002)
- Structural interpretation of site-directed mutagenesis and specificity of the catalytic subunit of protein kinase CK2 using comparative modelling. Srinivasan N, Antonelli M, Jacob G, Korn I, Romero F, Jedlicki A, Dhanaraj V, Sayed MF, Blundell TL, Allende CC, Allende JE. Protein Eng 12 119-127 (1999)
- Structure-based design of potent CDK1 inhibitors derived from olomoucine. Furet P, Zimmermann J, Capraro HG, Meyer T, Imbach P. J Comput Aided Mol Des 14 403-409 (2000)
- Synthesis and evaluation of 3-phenylpyrazolo[3,4-d]pyrimidine-peptide conjugates as Src kinase inhibitors. Kumar A, Wang Y, Lin X, Sun G, Parang K. ChemMedChem 2 1346-1360 (2007)
- 2D Autocorrelation, CoMFA, and CoMSIA modeling of protein tyrosine kinases' inhibition by substituted pyrido[2,3-d]pyrimidine derivatives. Caballero J, Fernández M, Saavedra M, González-Nilo FD. Bioorg Med Chem 16 810-821 (2008)
- MADAMM: a multistaged docking with an automated molecular modeling protocol. Cerqueira NM, Bras NF, Fernandes PA, Ramos MJ. Proteins 74 192-206 (2009)
- Chemical force microscopy with active enzymes. Fiorini M, McKendry R, Cooper MA, Rayment T, Abell C. Biophys J 80 2471-2476 (2001)
- Design, synthesis, and antiproliferative and CDK2-cyclin a inhibitory activity of novel flavopiridol analogues. Ahn YM, Vogeti L, Liu CJ, Santhapuram HK, White JM, Vasandani V, Mitscher LA, Lushington GH, Hanson PR, Powell DR, Himes RH, Roby KF, Ye Q, Georg GI. Bioorg Med Chem 15 702-713 (2007)
- Molecular scaffold-based design and comparison of combinatorial libraries focused on the ATP-binding site of protein kinases. Stahura FL, Xue L, Godden JW, Bajorath J. J Mol Graph Model 17 1-9, 51-2 (1999)
- Understanding and modulating cyclin-dependent kinase inhibitor specificity: molecular modeling and biochemical evaluation of pyrazolopyrimidinones as CDK2/cyclin A and CDK4/cyclin D1 inhibitors. Rossi KA, Markwalder JA, Seitz SP, Chang CH, Cox S, Boisclair MD, Brizuela L, Brenner SL, Stouten PF. J Comput Aided Mol Des 19 111-122 (2005)
- Structure-based drug design to the discovery of new 2-aminothiazole CDK2 inhibitors. Vulpetti A, Casale E, Roletto F, Amici R, Villa M, Pevarello P. J Mol Graph Model 24 341-348 (2006)
- Molecular modeling and dynamics simulation of human cyclin-dependent kinase 3 complexed with inhibitors. Perez PC, Caceres RA, Canduri F, de Azevedo WF. Comput Biol Med 39 130-140 (2009)
- A flavonoid gossypin binds to cyclin-dependent kinase 2. Kim H, Lee E, Kim J, Jung B, Chong Y, Ahn JH, Lim Y. Bioorg Med Chem Lett 18 661-664 (2008)
- An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors. Li Y, Gao W, Li F, Wang J, Zhang J, Yang Y, Zhang S, Yang L. Mol Biosyst 9 2266-2281 (2013)
- Analysis of CDK2 active-site hydration: a method to design new inhibitors. Kríz Z, Otyepka M, Bártová I, Koca J. Proteins 55 258-274 (2004)
- Identification of cylin-dependent kinase 1 inhibitors of a new chemical type by structure-based design and database searching. Furet P, Meyer T, Mittl P, Fretz H. J Comput Aided Mol Des 15 489-495 (2001)
- Synthesis of purin-2-yl and purin-6-yl-aminoglucitols as C-nucleosidic ATP mimics and biological evaluation as FGFR3 inhibitors. Tak-Tak L, Barbault F, Maurel F, Busca P, Le Merrer Y. Eur J Med Chem 46 1254-1262 (2011)
- Interaction energies for the purine inhibitor roscovitine with cyclin-dependent kinase 2: correlated ab initio quantum-chemical, DFT and empirical calculations. Dobes P, Otyepka M, Strnad M, Hobza P. Chemistry 12 4297-4304 (2006)
- N-(indazolyl)benzamido derivatives as CDK1 inhibitors: design, synthesis, biological activity, and molecular docking studies. Raffa D, Maggio B, Cascioferro S, Raimondi MV, Daidone G, Plescia S, Schillaci D, Cusimano MG, Titone L, Colomba C, Tolomeo M. Arch Pharm (Weinheim) 342 265-273 (2009)
- Comparative analysis of the surface interaction properties of the binding sites of CDK2, CDK4, and ERK2. Kelly MD, Mancera RL. ChemMedChem 1 366-375 (2006)
- Exponential repulsion improves structural predictability of molecular docking. Bazgier V, Berka K, Otyepka M, Banáš P. J Comput Chem 37 2485-2494 (2016)
- Morphogenesis signaling components influence cell cycle regulation by cyclin dependent kinase. Tobe BT, Kitazono AA, Garcia JS, Gerber RA, Bevis BJ, Choy JS, Chasman D, Kron SJ. Cell Div 4 12 (2009)
- Rt-PCR study of purinergic P2 receptors in hematopoietic cell lines. Bernhard MK, Ulrich K. Biochemistry (Mosc) 71 607-611 (2006)
- Comparative analysis of various electrostatic potentials on docking precision against cyclin-dependent kinase 2 protein: a multiple docking approach. Tripathi SK, Soundarya RN, Singh P, Singh SK. Chem Biol Drug Des 85 107-118 (2015)
- Catalysis of nucleophilic aromatic substitutions in the 2,6,8-trisubstituted purines and application in the synthesis of combinatorial libraries. Riva-Toniolo C, Müller S, Schaub J, Brill WK. Mol Divers 6 43-53 (2003)
- Expression, purification, and circular dichroism analysis of human CDK9. Leopoldino AM, Canduri F, Cabral H, Junqueira M, de Marqui AB, Apponi LH, da Fonseca IO, Domont GB, Santos DS, Valentini S, Bonilla-Rodriguez GO, Fossey MA, de Azevedo WF, Tajara EH. Protein Expr Purif 47 614-620 (2006)
- Influence of the Solvent on the Stability of Aminopurine Tautomers and Properties of the Amino Group. Jezuita A, Wieczorkiewicz PA, Krygowski TM, Szatylowicz H. Molecules 28 2993 (2023)
- Scaffold Hopping Approach to a New Series of Pyridine Derivatives as Potent Inhibitors of CDK2. Xu X, Yao Q. Arch Pharm (Weinheim) 349 224-231 (2016)